Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 1/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484676 | 1.00 | GABRA1 (0.61) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL8680640 | 0.86 | GABRA1 (0.64) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL31123826 | 0.86 | GABRA1 (0.64) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL39140 | 0.84 | HPGD (0.61) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL20853605 | 0.84 | GABRA1 (0.61) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL31011017 | 0.84 | HPGD (0.61) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL1635308 | 0.83 | GABRA1 (0.50) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL29567244 | 0.83 | GABRA1 (0.50) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| SCHEMBL19329438 | 0.82 | GABRA1 (0.59) | GABRA1LMNAGABRB2GABRG2GABRB3 | |
| Bicarbonate SCHEMBL236924 | 0.82 | GABRA1 (0.59) | GABRA1LMNAGABRB2GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132445-A1 | PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS | Hinye Pharmaceutical Co., Ltd. (CN) | 2024-04-25 | — | — | US | disclosed |
| EP-4286359-A1 | PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS | Hinye Pharmaceutical Co., Ltd. (CN) | 2023-12-06 | — | — | EP | disclosed |
| CN-115181369-A | No-blooming BIPB vulcanized ethylene propylene diene monomer rubber and preparation method thereof | 遂宁森帝汽配制造有限责任公司 | 2022-10-14 | — | — | CN | disclosed |
| WO-2022063254-A1 | PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 天地恒一制药股份有限公司 | 2022-03-31 | — | — | WO | disclosed |
| CN-114249652-A | Phenol derivative and application thereof in medicine | 天地恒一制药股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-105384607-B | A kind of cumene amphyl and preparation method thereof | 四川海思科制药有限公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-105384607-A | Isopropyl-phenol derivative and preparation method therefor | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2016-03-09 | — | — | CN | disclosed |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBVIE, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8350083-B2 | Antagonists of the TRPV1 receptor and uses thereof | ABBVIE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120283335-A1 | Analogs of Propofol, Preparation Thereof and Use as Anesthetics | SIGNATURE THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283335-A1 | Analogs of Propofol, Preparation Thereof and Use as Anesthetics | SIGNATURE THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
| US-8030504-B2 | Pain, especially, inflammatory hyperalgesia, ostheoarthritic pain, chronic lower pain, allodynia, migraine. Methods of controlling pain and treating bladder overactivity and urinary incontinence | ABBOTT LABORATORIES (US) | 2011-10-04 | — | — | US | disclosed |
| EP-2134678-A2 | N-(5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Abbott Laboratories (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008079683-A2 | N- (5, 6, 7, 8-TETRAHYDRONAPHTHALEN-1-YL) UREA DERIVATIVES AND RELATED COMPOUNDS AS TRPV1 VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153871-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GABRA1 399/4885LMNA 3622/4885GABRB2 704/4885 |
| US-20240132445-A1 | PHENOL DERIVATIVE AND APPLICATION THEREOF IN MEDICAMENTS | GABRA2, GABRA1, GABRA4 | GABRA1 2/4885LMNA 1497/4885GABRB2 7/4885 |
| US-20120283335-A1 | Analogs of Propofol, Preparation Thereof and Use as Anesthetics | GABRP, CYP4F11, CYP2F1 | GABRA1 14/4885LMNA 1435/4885GABRB2 67/4885 |
| US-20130165479-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GABRA1 390/4885LMNA 3166/4885GABRB2 647/4885 |
| US-20120022103-A1 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GABRA1 399/4885LMNA 3622/4885GABRB2 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.